Novartis Raises Annual Sales Growth Forecast After Restructuring

Swiss Stocks Are Lagging Eurozone Peers By the Most Since 1999

Novartis Lifts Outlook After Shedding Sandoz Generics

A Doctor With Brain Cancer Is Helping Transform Its Treatment

Novartis Spinoff Sandoz to Start Trading as Standalone Drugmaker

DEA Loosens ADHD Drug Production Controls Amid Shortage

Bain, Cinven Weighs Sale of €10 Billion Drugmaker Stada

European Stocks Edge Up as Investors Focus on Company Earnings

Novartis Raises Outlook, Plans Buyback of Up to $15 Billion

Novartis Sells Eye Drugs to Bausch for Up to $2.5 Billion

Carson Block’s Latest Short Bet Is Burned by Novartis M&A Deal

Credit Suisse's Exit From Stock Benchmark Shows Fading Heft of Swiss Financials